The abstract is read at the publisher; the summary is JClub's.
Retlirafusp alfa plus CAPOX significantly prolonged overall survival in previously untreated, unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, with median 16.8 vs 10.4 months in PD-L1 CPS ≥5 patients.
- Why it matters: The study addresses the need for effective first-line options in HER2-negative gastric or gastroesophageal junction adenocarcinoma, where outcomes remain limited and PD-L1–targeted strategies are being tested.
- What they did: In the randomized, double-blind RELIGHT phase III trial, 731 patients received retlirafusp alfa or placebo every 3 weeks plus capecitabine and oxaliplatin, with overall survival assessed in PD-L1 CPS ≥5 and intention-to-treat sets.
- The result: Overall survival also improved in the intention-to-treat analysis (15.8 vs 11.2 months; stratified HR 0.66), and progression-free survival increased in both PD-L1 CPS ≥5 and intention-to-treat groups, with grade ≥3 treatment-related adverse events comparable (62.6% vs 59.0%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.